vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Regency Centers (REG). Click either name above to swap in a different company.

BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($406.6M vs $404.2M, roughly 1.0× Regency Centers). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 50.1%, a 10.4% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs 8.5%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs 5.4%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Regency Centers Corporation is a real estate investment trust based in Jacksonville, Florida, and is one of the largest operators of shopping centers with grocery stores as anchor tenants. As of October 21, 2020, the company owned 415 properties comprising 56-million-square feet of space. Notable properties owned by the company include Serramonte Center and a 30% interest in Village District.

BCRX vs REG — Head-to-Head

Bigger by revenue
BCRX
BCRX
1.0× larger
BCRX
$406.6M
$404.2M
REG
Growing faster (revenue YoY)
BCRX
BCRX
+200.6% gap
BCRX
209.1%
8.5%
REG
Higher net margin
BCRX
BCRX
10.4% more per $
BCRX
60.5%
50.1%
REG
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
5.4%
REG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCRX
BCRX
REG
REG
Revenue
$406.6M
$404.2M
Net Profit
$245.8M
$202.5M
Gross Margin
97.7%
Operating Margin
64.0%
71.0%
Net Margin
60.5%
50.1%
Revenue YoY
209.1%
8.5%
Net Profit YoY
1017.5%
134.1%
EPS (diluted)
$1.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
REG
REG
Q4 25
$406.6M
$404.2M
Q3 25
$159.4M
$387.6M
Q2 25
$163.4M
$380.8M
Q1 25
$145.5M
$380.9M
Q4 24
$131.5M
$372.5M
Q3 24
$117.1M
$360.3M
Q2 24
$109.3M
$357.3M
Q1 24
$92.8M
$363.9M
Net Profit
BCRX
BCRX
REG
REG
Q4 25
$245.8M
$202.5M
Q3 25
$12.9M
$109.4M
Q2 25
$5.1M
$106.0M
Q1 25
$32.0K
$109.6M
Q4 24
$-26.8M
$86.5M
Q3 24
$-14.0M
$101.5M
Q2 24
$-12.7M
$102.7M
Q1 24
$-35.4M
$109.8M
Gross Margin
BCRX
BCRX
REG
REG
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Q1 24
98.6%
Operating Margin
BCRX
BCRX
REG
REG
Q4 25
64.0%
71.0%
Q3 25
18.6%
72.7%
Q2 25
18.2%
73.8%
Q1 25
14.6%
71.8%
Q4 24
-3.4%
71.1%
Q3 24
6.6%
72.5%
Q2 24
8.0%
72.3%
Q1 24
-15.6%
72.3%
Net Margin
BCRX
BCRX
REG
REG
Q4 25
60.5%
50.1%
Q3 25
8.1%
28.2%
Q2 25
3.1%
27.8%
Q1 25
0.0%
28.8%
Q4 24
-20.4%
23.2%
Q3 24
-12.0%
28.2%
Q2 24
-11.6%
28.7%
Q1 24
-38.1%
30.2%
EPS (diluted)
BCRX
BCRX
REG
REG
Q4 25
$1.13
Q3 25
$0.06
Q2 25
$0.02
Q1 25
$0.00
Q4 24
$-0.13
Q3 24
$-0.07
Q2 24
$-0.06
Q1 24
$-0.17

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
REG
REG
Cash + ST InvestmentsLiquidity on hand
$274.7M
Total DebtLower is stronger
$4.7B
Stockholders' EquityBook value
$-119.2M
$6.9B
Total Assets
$514.2M
$13.0B
Debt / EquityLower = less leverage
0.69×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
REG
REG
Q4 25
$274.7M
Q3 25
$212.9M
Q2 25
$260.0M
Q1 25
$295.1M
Q4 24
$320.9M
Q3 24
$96.8M
Q2 24
$78.4M
Q1 24
$84.3M
Total Debt
BCRX
BCRX
REG
REG
Q4 25
$4.7B
Q3 25
$4.9B
Q2 25
$4.8B
Q1 25
$4.6B
Q4 24
$4.4B
Q3 24
$4.4B
Q2 24
$4.4B
Q1 24
$4.4B
Stockholders' Equity
BCRX
BCRX
REG
REG
Q4 25
$-119.2M
$6.9B
Q3 25
$-387.9M
$6.8B
Q2 25
$-421.6M
$6.7B
Q1 25
$-451.9M
$6.7B
Q4 24
$-475.9M
$6.7B
Q3 24
$-468.6M
$6.8B
Q2 24
$-475.6M
$6.8B
Q1 24
$-476.2M
$7.0B
Total Assets
BCRX
BCRX
REG
REG
Q4 25
$514.2M
$13.0B
Q3 25
$446.4M
$13.1B
Q2 25
$457.2M
$12.7B
Q1 25
$480.0M
$12.6B
Q4 24
$490.4M
$12.4B
Q3 24
$491.3M
$12.4B
Q2 24
$472.4M
$12.4B
Q1 24
$467.9M
$12.7B
Debt / Equity
BCRX
BCRX
REG
REG
Q4 25
0.69×
Q3 25
0.72×
Q2 25
0.72×
Q1 25
0.69×
Q4 24
0.66×
Q3 24
0.65×
Q2 24
0.64×
Q1 24
0.63×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
REG
REG
Operating Cash FlowLast quarter
$292.0M
$203.9M
Free Cash FlowOCF − Capex
$291.2M
FCF MarginFCF / Revenue
71.6%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
1.19×
1.01×
TTM Free Cash FlowTrailing 4 quarters
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
REG
REG
Q4 25
$292.0M
$203.9M
Q3 25
$41.6M
$218.7M
Q2 25
$41.3M
$244.0M
Q1 25
$-27.5M
$161.0M
Q4 24
$-5.2M
$191.4M
Q3 24
$8.2M
$227.6M
Q2 24
$-1.4M
$203.5M
Q1 24
$-53.7M
$167.8M
Free Cash Flow
BCRX
BCRX
REG
REG
Q4 25
$291.2M
Q3 25
$40.3M
Q2 25
$41.1M
Q1 25
$-27.7M
Q4 24
$-5.9M
Q3 24
$8.2M
Q2 24
$-1.5M
Q1 24
$-53.9M
FCF Margin
BCRX
BCRX
REG
REG
Q4 25
71.6%
Q3 25
25.3%
Q2 25
25.2%
Q1 25
-19.0%
Q4 24
-4.5%
Q3 24
7.0%
Q2 24
-1.4%
Q1 24
-58.1%
Capex Intensity
BCRX
BCRX
REG
REG
Q4 25
0.2%
Q3 25
0.8%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.3%
Cash Conversion
BCRX
BCRX
REG
REG
Q4 25
1.19×
1.01×
Q3 25
3.23×
2.00×
Q2 25
8.12×
2.30×
Q1 25
-859.91×
1.47×
Q4 24
2.21×
Q3 24
2.24×
Q2 24
1.98×
Q1 24
1.53×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

Segment breakdown not available.

REG
REG

Shopping Centers$418.0M103%
Propertymanagementservices$4.1M1%
Assetmanagementservices$1.7M0%

Related Comparisons